Mavorixafor Side Effects
Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.
Applies to mavorixafor: oral capsules.
Side effects include:
Most common adverse effects (incidence >10% and at a frequency higher than placebo): thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting, dizziness.
For healthcare professionals
Applies to mavorixafor: oral capsule.
General adverse events
The most common adverse reactions (10% or greater) were: thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting and dizziness.[Ref]
Gastrointestinal
- Very common (10% or more): Vomiting (14%)[Ref]
Dermatologic
- Very common (10% or more): Pityriasis (14%), rash (14%)[Ref]
Hematologic
- Very common (10% or more): Thrombocytopenia (21%)[Ref]
Cardiovascular
- Frequency not reported: QTc interval prolongation[Ref]
Nervous system
- Very common (10% or more): Dizziness (14%)[Ref]
Respiratory
- Very common (10% or more): Rhinitis (14%), epistaxis (14%)[Ref]
References
1. (2024) "Product Information. Xolremdi (mavorixafor)." X4 Pharmaceuticals, Inc.
More about mavorixafor
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: other immunostimulants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Mavorixafor side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
